Tem Group has been acquired by Instrumentation Laboratory
The shareholders of Tem Group (TEM) have sold the company to Instrumentation Laboratory (IL). Financial details have not been disclosed.
TEM is a global leader in in-vitro diagnostic (IVD) testing for Patient Blood Management (PBM) with their flagship ROTEM testing systems. With a direct sales force in seven markets, including the USA, TEM has consistently achieved above market growth in the PBM market. In hospital trauma and surgical patients with clinically significant bleeding, ROTEM whole blood analyzers provide a rapid differential diagnosis of coagulopathies. This supports targeted transfusion and coagulation factor concentrate therapy and, as a result, is key to PBM programs. PBM is a multi-disciplinary, evidence-based medical concept, optimizing a patient’s own blood volume, minimizing blood loss and thereby significantly reducing or avoiding blood transfusion.
IL, founded in 1959 and based in Bedford, Massachusetts, is a worldwide developer, manufacturer and distributor of in-vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The company’s product lines include critical care systems, hemostasis systems and information management systems. IL is an integral part of the Werfen family of companies which distributes its products by a direct sales force in North America and Werfen organizations around the globe.
"A passion for innovation, leading systems and extensive knowledge in PBM, make TEM a perfect complement to our focus, commitment, and leadership in hemostasis and critical care IVD," said Ramon Benet, CEO at IL. "IL and our global Werfen organizations are ideally positioned to maximize the potential of the ROTEM product line, which intersects our existing business and presents synergies in our core competencies and customer call points. Most importantly, ROTEM systems share the same ultimate benefit of all our products, to help customers reduce overall hospital costs, while improving patient care."
Oaklins' team in Switzerland advised the seller in this transaction.
Talk to the deal team
Related deals
Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.
Learn moreCreo Medical Group plc has completed a US$15.7 million equity fundraise
Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
Learn moreSpringwell Veterinary Surgery has been transferred to an Employee Ownership Trust
Springwell Veterinary Surgery has become employee owned after transferring into an Employee Ownership Trust (EOT).
Learn more